Intellicyt

About:

IntelliCyt Corporation develops and markets high-throughput cell and bead-based screening solutions for the use of life sciences.

Website: http://intellicyt.com

Twitter/X: intellicyt

Top Investors: Arboretum Ventures, New Mexico Community Capital, Oxford Finance LLC, Prolog Ventures, Verge Fund

Description:

IntelliCyt Corporation develops and markets innovative high-throughput cell and bead-based screening solutions for use throughout the life sciences. The Company uses proprietary technologies to create instrumentation, reagent kits, and software products that dramatically increase the speed and decrease the cost of detecting and measuring cells and beads. IntelliCyt’s products address a pervasive need among pharmaceutical, biotechnology, and life science research laboratories to achieve increased productivity while adapting to the accelerating pace and increasing complexity of modern life sciences. Founded in 2006 by life science entrepreneurs and leading scientists, IntelliCyt Corporation was the first to commercialize a true high throughput screening platform for suspension cells that addresses urgent unmet needs in phenotypic small molecule drug discovery, antibody discovery, in vitro toxicology as well as other high profile research areas. By combining the sensitive, proven detection technology of flow cytometry with a patented sample processing technology, IntelliCyt’s HTFC Screening System enables suspension cell assays at speeds up to 40x faster than traditional flow cytometry. IntelliCyt has integrated HTFC with application-specific reagent kits and informatics software to address the growing market for high throughput cell based assays to provide earlier, more physiologically relevant results at lower cost.

Total Funding Amount:

$24.8M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Albuquerque, New Mexico, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)intellicyt.com

Founders:

R.Terry Dunlay

Number of Employees:

11-50

Last Funding Date:

2015-10-22

IPO Status:

Private

Industries:

© 2025 bioDAO.ai